Cost of Multiple Sclerosis Rx Soaring, Even for Older Meds

This article originally appeared here.
Share this content:
Cost of Multiple Sclerosis Rx Soaring, Even for Older Meds
Cost of Multiple Sclerosis Rx Soaring, Even for Older Meds

MONDAY, April 27, 2015 (HealthDay News) -- The cost of multiple sclerosis (MS) medications in the United States is rising five to seven times faster than the normal rate of drug inflation, according to a study published online April 24 in Neurology.

"The issue of astronomical drug costs, especially for newer drugs or rare conditions, is more and more common," study author Daniel Hartung, Pharm.D., M.P.H., an associate professor at the Oregon State University/Oregon Health & Science University College of Pharmacy in Portland, said in a university news release. Currently, there are no MS drugs in the United States with a list price below $50,000 a year, which is two to three times higher than in Australia, Canada, or the United Kingdom, the researchers added.

First-generation MS drugs became available in the 1990s at prices ranging from $8,000 to $10,000 a year. But the prices of those drugs did not go down or stay steady after newer drugs became available, which is what typically occurs. Instead, the costs of those older drugs soared. For example, one that originally cost $8,700 a year now costs $62,400 a year, the researchers said.

The cause of the massive price increases for the older drugs is unexplained and "alarming," the authors added. "The simplest explanation is that pharmaceutical companies raise prices of new and old MS disease-modifying therapies in the United States to increase profits, and our health care system puts no limits on these increases," the study authors write.

Abstract
Full Text
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Global Prevalence of Insufficient Activity 27.5 Percent

Global Prevalence of Insufficient Activity 27.5 Percent

Levels of insufficient physical activity stable between 2001, 2016; increase seen in high-income countries

HTN Tx Intensification Common Upon Discharge in U.S. Vets

HTN Tx Intensification Common Upon Discharge in U.S. ...

Fourteen percent of older adults admitted to hospital for non-cardiac conditions had intensification of tx

Quarterly Canakinumab Reduces Risk for Gout Attacks

Quarterly Canakinumab Reduces Risk for Gout Attacks

Doesn't affect serum uric acid levels over time, but targets interleukin-1β

is free, fast, and customized just for you!




Already a member?

Sign In Now »